[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-445693-105":59,"doc-detail-445693-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pp42-comprehensive-care-program-for-polypharmacy-patients-cafam-experience-healthcare-provider-institution-pharmaceutical-manager","PP42 - Comprehensive Care Program For Polypharmacy Patients - Cafam Experience - Healthcare Provider Institution - Pharmaceutical Manager","","A before-and-after intervention evaluated comprehensive care for persistent excessive polypharmacy in 661 patients aged over 74 years. Guided by a primary care team led by a family doctor and supported by the Cafam pharmaceutical manager’s pharmacoepidemiology area, medication regimens were assessed after 6 and 12 months using dispensing history. Medication adjustments occurred in 36%, none were needed in 35%, and interventions could not be executed in 29%. Results included a 20% reduction in stomach acid disorder agents and a year-one net cost reduction of COP67,387,362 (USD16,846).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pp42-comprehensive-care-program-for-polypharmacy-patients-cafam-experience-healthcare-provider-institution-pharmaceutical-manager/445693/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pp42-comprehensive-care-program-for-polypharmacy-patients-cafam-experience-healthcare-provider-institution-pharmaceutical-manager/445693.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the comprehensive care program for polypharmacy patients?","Question",{"text":112,"@type":113},"To improve pharmacotherapy by reducing the number of prescribed drugs and promoting rational use of health technologies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the intervention implemented and evaluated?",{"text":117,"@type":113},"A primary care team led by a family doctor, supported by Cafam’s pharmacoepidemiology area, adjusted medications; outcomes were assessed after 6 and 12 months via the pharmacy manager’s dispensing history.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the overall medication adjustment outcomes for the cohort?",{"text":121,"@type":113},"Adjustments were made for 36% of patients, no modification was needed for 35%, and intervention was not possible for 29%.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},445693,1790792369,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","PP41 Effect Of SGLT2 Inhibitors On Renal Outcomes According To Glomerular Filtration Rate: Systematic Review Applying Clinical Benefit Thresholds  \nFernando Tortosa,  \nSantiago Torales ([santiago.torales@gmail.com](santiago.torales@gmail.com)), Florencia Alcoba and Emanuel Medina  \nIntroduction: Effects of sodium-glucose transport protein 2 inhibitor (SGLT2i) on diabetes, cardiovascular, and renal outcomes have been shown in the evidence, partially disaggregating results according to glomerular filtration rate (GFR) subgroups, which limits the ability to identify relevant benefits. In addition, when specific renal outcomes were analyzed, no thresholds were established to define clinical relevance. A review of evidence by specific GFR levels for critical outcomes was proposed, as defined by clinical benefit thresholds. Methods: We conducted a systematic review using the PRISMA checklist, searching relevant databases for double-blind controlled trials of 1,000 or more patients with a duration longer than six months, SGLT2i use, and results disaggregated by GFR levels. Based on utilities, thresholds were expressed as minimum important detectable (MID) events of absolute effect reduction (AER) per 1,000 individuals for death (MID=10), GFR deterioration (MID=22), and composite renal outcome (MID=16) . The Credibility of Effect Modification Analyses (ICEMAN) tool was used to assess effect modification credibility.  \nResults: Thirteen studies were selected (90,403 patients, 75% diabetic, mean initial estimated GFR of 61 mL/minute per 1 .73 m2) .  \n• Mortality: GFR (\u003C60): 22,816 patients, relative risk (RR) 0.91 (95% CI: 0.82, 1.01), AER 0.3 percent, null effect, high certainty; GFR (>60): 55,037patients, RR 0.89 (95% CI: 0.83, 0.96), AER 1.5 percent, probable reduction, moderate certainty.  \n• GFR deterioration: GFR (30 to 45): 9,335 patients, RR 0.76 (95% Ci: 0.61, 0.95), AER 3.4 percent, slight reduction, moderate certainty; GFR (45 to 60): 9,245 patients, RR 0.54 (95% CI: 0.45, 0.66), AER 1.9 percent, small or null effect, high certainty; GFR (>60): 43,635patients, RR 0.61 (95% CI: 0.48, 0.78), AER 0.8 percent, null effect, high certainty.  \n• Composite renal outcome: GFR (\u003C60): 27,114 patients, RR 0.83 (95% CI: 0.63, 1.08), AER 1.5 percent, slight reduction, low certainty; GFR (>60): 60,422 patients, RR 0.70 (95% CI: 0.58, 0.86), AER 0.9 percent, minimal reduction, moderate certainty.  \nConclusions: SGLT2i may have relevant effects in patients with a GFR less than 60, with slight reductions in mortality rate and improvements in clinically important composite renal outcomes. When the GFR is greater than 60, the benefits are uncertain or not clinically relevant, underlining the importance of individually tailored treatments considering renal function for each patient.  \nPP42 Comprehensive Care Program For Polypharmacy Patients: Cafam Experience (Healthcare Provider Institution – Pharmaceutical Manager)  \nJesus Ocana ([jhoc1987@gmail.com](jhoc1987@gmail.com)), Carolina Parra, Javier Urrego and Leal Guillermo  \nIntroduction: We live in an increasingly long-lived society with rising rates of multimorbidity, which requires the formulation of multiple medications to treat chronic conditions. This can result in polypharmacy (the use of more than five medications in the same month)with consumption maintained overtime, making it necessary for health policies and professionals to jointly resolve this issue to reduce the associated health risks.  \nMethods: We conducted a before-and-after intervention study in661 patients over 74 years of age with persistent excessive polypharmacy (≥ 10 medications for more than six months) . The intervention was carried out by the Healthcare Provider Institution primary care team led by a family doctor, accompanied by the pharmacoepidemiology area of the Cafam pharmaceutical manager. After six and 12 months of intervention (a time established to notice the effects ofthe adjustment), the patients’ medications","cbCaiuSv5fO2KA6x","https://ap.wps.com/l/cbCaiuSv5fO2KA6x","pdf",34067,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the main goal of the comprehensive care program for polypharmacy patients?\",\"answer\":\"To improve pharmacotherapy by reducing the number of prescribed drugs and promoting rational use of health technologies.\"},{\"question\":\"How was the intervention implemented and evaluated?\",\"answer\":\"A primary care team led by a family doctor, supported by Cafam’s pharmacoepidemiology area, adjusted medications; outcomes were assessed after 6 and 12 months via the pharmacy manager’s dispensing history.\"},{\"question\":\"What were the overall medication adjustment outcomes for the cohort?\",\"answer\":\"Adjustments were made for 36% of patients, no modification was needed for 35%, and intervention was not possible for 29%.\"}]","PP42 - Comprehensive Care Program For Polypharmacy Patients - Cafam Experience - Healthcare Provider Institution - Pharmaceutical Manager | PDF",1790712566]